There are current trials investigating the effect of resveratrol supplementation on lipid profiles and liver enzymes among patients with metabolic syndrome (MetS) and related disorders; however, their findings are controversial. This systematic review and meta-analysis were aimed to determine the effects of resveratrol supplementation on lipid profiles and liver enzymes among patients with MetS and related disorders. We performed a comprehensive search of the following online databases up to November 2018: Cochrane Library, PubMed, Embase, and Web of Science. The relevant articles were assessed for quality of studies using the Cochrane risk of bias tool. Out of 2459 citations, 31 articles were appropriate for including to the current meta-analysis. The pooled results indicated that resveratrol use significantly decreased total cholesterol [weighted mean difference (WMD) = − 7.65 mg/dL; 95% CI, − 12.93, − 2.37; P < 0.01; I2: 83.4%] and increased gamma-glutamyl transferase (GGT) concentrations (WMD = 1.76 U/l; 95% CI, 0.58, 2.94; P < 0.01; I2: 20.1%). We found no significant effect of resveratrol supplementation on triglycerides (WMD = − 5.84 mg/dL; 95% CI, − 12.68, 1.00; P = 0.09; I2: 66.8%), LDL- (WMD = -2.90 mg/dL; 95% CI, − 10.88, 5.09; P = 0.47; I2: 96.0%), HDL-cholesterol (WMD = 0.49 mg/dL; 95% CI, − 0.80, 1.78; P = 0.45; I2: 74.0%), alanine aminotransferase (ALT) (WMD = -0.14 U/l; 95% CI, − 3.69, 3.41; P = 0.93; I2: 79.6%), and aspartate aminotransferase (AST) (WMD = -0.34 U/l; 95% CI, − 2.94, 2.27; P = 0.80; I2: 88.0%) concentrations. This meta-analysis demonstrated that resveratrol supplementation among patients with MetS and related disorders significantly reduced total cholesterol and increased GGT concentrations, but did not affect triglycerides, LDL-, HDL-cholesterol, ALT, and AST concentrations. This data suggests that resveratrol may have a potential cardio-protective effect in patients with MetS and related disorders.

中文翻译：

---

白藜芦醇对代谢综合征和相关疾病患者血脂和肝酶的影响：随机对照试验的系统评价和荟萃分析

目前有一些试验研究补充白藜芦醇对代谢综合症（MetS）及相关疾病患者的血脂和肝酶的影响。然而，他们的发现是有争议的。这项系统的回顾和荟萃分析旨在确定白藜芦醇补充剂对MetS及相关疾病患者血脂和肝酶的影响。截至2018年11月，我们对以下在线数据库进行了全面搜索：Cochrane图书馆，PubMed，Embase和Web of Science。使用Cochrane偏倚风险工具评估了相关文章的研究质量。在2459篇文献中，有31篇文章适合纳入当前的荟萃分析。汇总结果表明，白藜芦醇的使用显着降低了总胆固醇[加权平均差异（WMD）=-7.65 mg / dL；95％CI，-12.93，-2.37；P <0.01；I2：83.4％]和增加的γ-谷氨酰转移酶（GGT）浓度（WMD = 1.76 U / l； 95％CI，0.58、2.94； P <0.01； I2：20.1％）。我们发现白藜芦醇补充剂对甘油三酸酯（WMD =-5.84 mg / dL; 95％CI，-12.68，1.00; P = 0.09; I2：66.8％），LDL-（WMD = -2.90 mg / dL; 95）没有显着影响％CI，− 10.88，5.09; P = 0.47; I2：96.0％），HDL-胆固醇（WMD = 0.49 mg / dL; 95％CI，− 0.80，1.78; P = 0.45; I2：74.0％），丙氨酸氨基转移酶（ALT）（WMD = -0.14 U / l; 95％CI，-3.69，3.41; P = 0.93; I2：79.6％）和天冬氨酸转氨酶（AST）（WMD = -0.34 U / l; 95％CI， − 2.94，2.27; P = 0.80; I2：88.0％）浓度。这项荟萃分析表明，在MetS和相关疾病患者中补充白藜芦醇可显着降低总胆固醇并增加GGT浓度，但不影响甘油三酸酯，LDL-，HDL-胆固醇，ALT和AST浓度。该数据表明白藜芦醇对患有MetS和相关疾病的患者可能具有潜在的心脏保护作用。